More than 800 exhibitors are expected to participate, showcasing technologies and solutions spanning pharmaceutical ingredients, biotechnology, AI and contract services, finished dosage forms and more
The Danish biotech said it will move petrelintide into registrational Phase 3 trials in the second half of 2026 after Phase 2 results showed double-digit weight loss and a tolerability profile largely comparable to placebo
The initiative tackled everyday health concerns through interactive activities rather than conventional classroom lessons
API manufacturer's revenue climbs to Rs. 189.75 crore as Asia overtakes Europe as top market, while company advances new launches in ADHD and anaesthetic segments
Consolidated revenue drops to Rs. 7,944 million against a high base in Q1 FY26, even as EBITDA margin recovers sequentially
Total revenue from operations for the quarter stood at Rs. 37,402 million, up 10.9% year-over-year
Moody’s Ratings upgraded Teva’s corporate credit rating to Baa3 from Ba1
Adjusted EBITDA climbs 30.7% to Rs. 65.1 crore as treatments cross 10.3 lakh; network expands to 550 clinics across five countries
Revenue from operations rises to Rs. 39.92 crore as company reports Rs. 20.78 crore quarterly loss amid higher research and development expenses
The workshop provided participants with cross-sector perspectives on regulatory, innovation and intellectual property pathways, while strengthening industry-academia engagement around the process of taking pharma innovations
The company announced updates to Allergan Partner Privileges
The quarter marked another step in its transformation from an API-focused business into a focused, debt-free finished dosage formulations (FDF) platform
Our partnership with Sesderma is built on a shared commitment to scientific excellence, innovation, and delivering advanced derma-tech in India
Consolidated EBITDA excluding real estate stood at Rs. 22.3 crore, declining 37% YoY and 10% QoQ
Drug formulations and biologicals remained the largest export category, contributing USD 5.98 billion and accounting for 73.85% of total pharmaceutical exports
Company's profit before tax increased 39% year-on-year to Rs. 435 crore, while profit after tax rose 47% to Rs. 317 crore from Rs. 215.5 crore in Q1 FY26
The three-day event will bring together pharmaceutical manufacturers, biotech companies, regulators, consultants, suppliers and technology innovators
The transaction is expected to close in Q4 2026, subject to applicable Indian regulatory requirements and customary closing conditions
The company invested Rs. 642 crore in R&D during the quarter, representing 8% of revenues, while organic capex stood at Rs. 585 crore
Subscribe To Our Newsletter & Stay Updated
